Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 523

1.

High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma.

Polifka I, Agaimy A, Herrmann E, Spath V, Trojan L, Stöckle M, Becker F, Ströbel P, Wülfing C, Schrader AJ, Barth P, Staehler M, Stief C, Hohenfellner M, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Höfler H, Haferkamp A, Geppert CI, Stöhr C, Hartmann A; German Network Of Kidney Cancer.

Hum Pathol. 2019 Jan;83:212-223. doi: 10.1016/j.humpath.2018.08.006. Epub 2018 Aug 17.

PMID:
30121370
2.

Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1.

Ettl J, Klein E, Hapfelmeier A, Grosse Lackmann K, Paepke S, Petry C, Specht K, Wolff L, Höfler H, Kiechle M.

PLoS One. 2017 Sep 6;12(9):e0183917. doi: 10.1371/journal.pone.0183917. eCollection 2017.

3.

Analysis of mammalian gene function through broad-based phenotypic screens across a consortium of mouse clinics.

de Angelis MH, Nicholson G, Selloum M, White J, Morgan H, Ramirez-Solis R, Sorg T, Wells S, Fuchs H, Fray M, Adams DJ, Adams NC, Adler T, Aguilar-Pimentel A, Ali-Hadji D, Amann G, André P, Atkins S, Auburtin A, Ayadi A, Becker J, Becker L, Bedu E, Bekeredjian R, Birling MC, Blake A, Bottomley J, Bowl M, Brault V, Busch DH, Bussell JN, Calzada-Wack J, Cater H, Champy MF, Charles P, Chevalier C, Chiani F, Codner GF, Combe R, Cox R, Dalloneau E, Dierich A, Di Fenza A, Doe B, Duchon A, Eickelberg O, Esapa CT, El Fertak L, Feigel T, Emelyanova I, Estabel J, Favor J, Flenniken A, Gambadoro A, Garrett L, Gates H, Gerdin AK, Gkoutos G, Greenaway S, Glasl L, Goetz P, Da Cruz IG, Götz A, Graw J, Guimond A, Hans W, Hicks G, Hölter SM, Höfler H, Hancock JM, Hoehndorf R, Hough T, Houghton R, Hurt A, Ivandic B, Jacobs H, Jacquot S, Jones N, Karp NA, Katus HA, Kitchen S, Klein-Rodewald T, Klingenspor M, Klopstock T, Lalanne V, Leblanc S, Lengger C, le Marchand E, Ludwig T, Lux A, McKerlie C, Maier H, Mandel JL, Marschall S, Mark M, Melvin DG, Meziane H, Micklich K, Mittelhauser C, Monassier L, Moulaert D, Muller S, Naton B, Neff F, Nolan PM, Nutter LM, Ollert M, Pavlovic G, Pellegata NS, Peter E, Petit-Demoulière B, Pickard A, Podrini C, Potter P, Pouilly L, Puk O, Richardson D, Rousseau S, Quintanilla-Fend L, Quwailid MM, Racz I, Rathkolb B, Riet F, Rossant J, Roux M, Rozman J, Ryder E, Salisbury J, Santos L, Schäble KH, Schiller E, Schrewe A, Schulz H, Steinkamp R, Simon M, Stewart M, Stöger C, Stöger T, Sun M, Sunter D, Teboul L, Tilly I, Tocchini-Valentini GP, Tost M, Treise I, Vasseur L, Velot E, Vogt-Weisenhorn D, Wagner C, Walling A, Weber B, Wendling O, Westerberg H, Willershäuser M, Wolf E, Wolter A, Wood J, Wurst W, Yildirim AÖ, Zeh R, Zimmer A, Zimprich A; EUMODIC Consortium, Holmes C, Steel KP, Herault Y, Gailus-Durner V, Mallon AM, Brown SD.

Nat Genet. 2015 Sep;47(9):969-978. doi: 10.1038/ng.3360. Epub 2015 Jul 27.

4.

Synthetic-wavelength interferometry improved with frequency calibration and unambiguity range extension.

Weimann C, Fratz M, Wölfelschneider H, Freude W, Höfler H, Koos C.

Appl Opt. 2015 Jul 10;54(20):6334-43. doi: 10.1364/AO.54.006334.

PMID:
26193412
5.

Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria.

von Laffert M, Warth A, Penzel R, Schirmacher P, Kerr KM, Elmberger G, Schildhaus HU, Büttner R, Lopez-Rios F, Reu S, Kirchner T, Pauwels P, Specht K, Drecoll E, Höfler H, Aust D, Baretton G, Bubendorf L, Stallmann S, Fisseler-Eckhoff A, Soltermann A, Tischler V, Moch H, Penault-Llorca F, Hager H, Schäper F, Lenze D, Hummel M, Dietel M.

J Thorac Oncol. 2014 Nov;9(11):1685-92. doi: 10.1097/JTO.0000000000000332.

6.

Participation in and support of clinical studies and other scientific investigations - Statement of the German Society for Pathology.

Röcken C, Höfler H, Hummel M, Meyermann R, Zietz C, Schirmacher P.

Pathol Res Pract. 2014 Nov;210(11):705-12. doi: 10.1016/j.prp.2014.09.001. Epub 2014 Sep 18.

PMID:
25305148
7.

Additive impact of HER2-/PTK6-RNAi on interactions with HER3 or IGF-1R leads to reduced breast cancer progression in vivo.

Falkenberg N, Anastasov N, Höfig I, Bashkueva K, Lindner K, Höfler H, Rosemann M, Aubele M.

Mol Oncol. 2015 Jan;9(1):282-94. doi: 10.1016/j.molonc.2014.08.012. Epub 2014 Sep 6.

8.

De novo discovery of phenotypic intratumour heterogeneity using imaging mass spectrometry.

Balluff B, Frese CK, Maier SK, Schöne C, Kuster B, Schmitt M, Aubele M, Höfler H, Deelder AM, Heck A Jr, Hogendoorn PC, Morreau J, Maarten Altelaar AF, Walch A, McDonnell LA.

J Pathol. 2015 Jan;235(1):3-13. doi: 10.1002/path.4436. Epub 2014 Nov 3.

PMID:
25201776
9.

Evaluation of colon cancer histomorphology: a comparison between formalin and PAXgene tissue fixation by an international ring trial.

Gündisch S, Slotta-Huspenina J, Verderio P, Ciniselli CM, Pizzamiglio S, Schott C, Drecoll E, Viertler C, Zatloukal K, Kap M, Riegman P, Esposito I, Specht K, Babaryka G, Asslaber M, Bodó K, den Bakker M, den Hollander J, Fend F, Neumann J, Reu S, Perren A, Langer R, Lugli A, Becker I, Richter T, Kayser G, May AM, Carneiro F, Lopes JM, Sobin L, Höfler H, Becker KF.

Virchows Arch. 2014 Nov;465(5):509-19. doi: 10.1007/s00428-014-1624-4. Epub 2014 Aug 2.

PMID:
25085759
10.

Activation of the PI3K/AKT pathway correlates with prognosis in stage II colon cancer.

Malinowsky K, Nitsche U, Janssen KP, Bader FG, Späth C, Drecoll E, Keller G, Höfler H, Slotta-Huspenina J, Becker KF.

Br J Cancer. 2014 Apr 15;110(8):2081-9. doi: 10.1038/bjc.2014.100. Epub 2014 Mar 11.

11.

A multifactorial histopathologic score for the prediction of prognosis of resected esophageal adenocarcinomas after neoadjuvant chemotherapy.

Langer R, Becker K, Zlobec I, Gertler R, Sisic L, Büchler M, Lordick F, Slotta-Huspenina J, Weichert W, Höfler H, Feith M, Ott K.

Ann Surg Oncol. 2014 Mar;21(3):915-21. doi: 10.1245/s10434-013-3410-y. Epub 2013 Nov 27.

PMID:
24281419
12.

Variation in cell signaling protein expression may introduce sampling bias in primary epithelial ovarian cancer.

Mittermeyer G, Malinowsky K, Beese C, Höfler H, Schmalfeldt B, Becker KF, Avril S.

PLoS One. 2013 Oct 28;8(10):e77825. doi: 10.1371/journal.pone.0077825. eCollection 2013.

13.

Reply to letter: "Tumor regression after neoadjuvant chemotherapy in gastric carcinoma: are there really so few responders?".

Langer R, Reim D, Höfler H, Becker K.

Ann Surg. 2014 Feb;259(2):e30. doi: 10.1097/SLA.0000000000000280. No abstract available.

14.

MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion.

Falkenberg N, Anastasov N, Rappl K, Braselmann H, Auer G, Walch A, Huber M, Höfig I, Schmitt M, Höfler H, Atkinson MJ, Aubele M.

Br J Cancer. 2013 Nov 12;109(10):2714-23. doi: 10.1038/bjc.2013.625. Epub 2013 Oct 15.

15.

Prevalence and topography of lymph node metastases in early esophageal and gastric cancer.

Gertler R, Stein HJ, Schuster T, Rondak IC, Höfler H, Feith M.

Ann Surg. 2014 Jan;259(1):96-101. doi: 10.1097/SLA.0000000000000239.

PMID:
24096772
16.

[Participation and support of clinical studies and other scientific investigations. Statement of the German Society for Pathology].

Röcken C, Höfler H, Hummel M, Meyermann R, Zietz C, Schirmacher P.

Pathologe. 2013 Sep;34(5):466-75. doi: 10.1007/s00292-013-1793-y. German.

PMID:
23881237
17.

Rapamycin extends murine lifespan but has limited effects on aging.

Neff F, Flores-Dominguez D, Ryan DP, Horsch M, Schröder S, Adler T, Afonso LC, Aguilar-Pimentel JA, Becker L, Garrett L, Hans W, Hettich MM, Holtmeier R, Hölter SM, Moreth K, Prehn C, Puk O, Rácz I, Rathkolb B, Rozman J, Naton B, Ordemann R, Adamski J, Beckers J, Bekeredjian R, Busch DH, Ehninger G, Graw J, Höfler H, Klingenspor M, Klopstock T, Ollert M, Stypmann J, Wolf E, Wurst W, Zimmer A, Fuchs H, Gailus-Durner V, Hrabe de Angelis M, Ehninger D.

J Clin Invest. 2013 Aug;123(8):3272-91. doi: 10.1172/JCI67674. Epub 2013 Jul 25.

18.

A specific expression profile of heat-shock proteins and glucose-regulated proteins is associated with response to neoadjuvant chemotherapy in oesophageal adenocarcinomas.

Slotta-Huspenina J, Wolff C, Drecoll E, Feith M, Bettstetter M, Malinowsky K, Bauer L, Becker K, Ott K, Höfler H, Becker KF, Langer R.

Br J Cancer. 2013 Jul 23;109(2):370-8. doi: 10.1038/bjc.2013.319. Epub 2013 Jul 9.

19.

Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways.

Schlitter AM, Born D, Bettstetter M, Specht K, Kim-Fuchs C, Riener MO, Jeliazkova P, Sipos B, Siveke JT, Terris B, Zen Y, Schuster T, Höfler H, Perren A, Klöppel G, Esposito I.

Mod Pathol. 2014 Jan;27(1):73-86. doi: 10.1038/modpathol.2013.112. Epub 2013 Jul 5.

20.

An ENU mutagenesis-derived mouse model with a dominant Jak1 mutation resembling phenotypes of systemic autoimmune disease.

Sabrautzki S, Janas E, Lorenz-Depiereux B, Calzada-Wack J, Aguilar-Pimentel JA, Rathkolb B, Adler T, Cohrs C, Hans W, Diener S, Fuchs H, Gailus-Durner V, Busch DH, Höfler H, Ollert M, Strom TM, Wolf E, Neff F, Hrabě de Angelis M.

Am J Pathol. 2013 Aug;183(2):352-68. doi: 10.1016/j.ajpath.2013.04.027. Epub 2013 Jun 19.

PMID:
23791841
21.

Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria.

Aichler M, Elsner M, Ludyga N, Feuchtinger A, Zangen V, Maier SK, Balluff B, Schöne C, Hierber L, Braselmann H, Meding S, Rauser S, Zischka H, Aubele M, Schmitt M, Feith M, Hauck SM, Ueffing M, Langer R, Kuster B, Zitzelsberger H, Höfler H, Walch AK.

J Pathol. 2013 Aug;230(4):410-9. doi: 10.1002/path.4199.

PMID:
23592244
22.

The impact of cysteine-rich intestinal protein 1 (CRIP1) in human breast cancer.

Ludyga N, Englert S, Pflieger K, Rauser S, Braselmann H, Walch A, Auer G, Höfler H, Aubele M.

Mol Cancer. 2013 Apr 9;12:28. doi: 10.1186/1476-4598-12-28.

23.

MALDI imaging mass spectrometry in cancer research: combining proteomic profiling and histological evaluation.

Schöne C, Höfler H, Walch A.

Clin Biochem. 2013 Apr;46(6):539-45. doi: 10.1016/j.clinbiochem.2013.01.018. Epub 2013 Feb 4. Review.

PMID:
23388677
24.

Effects of simultaneous knockdown of HER2 and PTK6 on malignancy and tumor progression in human breast cancer cells.

Ludyga N, Anastasov N, Rosemann M, Seiler J, Lohmann N, Braselmann H, Mengele K, Schmitt M, Höfler H, Aubele M.

Mol Cancer Res. 2013 Apr;11(4):381-92. doi: 10.1158/1541-7786.MCR-12-0378. Epub 2013 Jan 30.

25.

Prognostic implications of the seventh edition of the international union against cancer classification for patients with gastric cancer: the Western experience of patients treated in a single-center European institution.

Reim D, Loos M, Vogl F, Novotny A, Schuster T, Langer R, Becker K, Höfler H, Siveke J, Bassermann F, Friess H, Schuhmacher C.

J Clin Oncol. 2013 Jan 10;31(2):263-71. doi: 10.1200/JCO.2012.44.4315. Epub 2012 Dec 3.

PMID:
23213098
26.

Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome.

Bettstetter M, Berezowska S, Keller G, Walch A, Feuchtinger A, Slotta-Huspenina J, Feith M, Drecoll E, Höfler H, Langer R.

Hum Pathol. 2013 May;44(5):829-36. doi: 10.1016/j.humpath.2012.08.005. Epub 2012 Nov 14.

PMID:
23158210
27.

Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping.

Wulfkuhle JD, Berg D, Wolff C, Langer R, Tran K, Illi J, Espina V, Pierobon M, Deng J, DeMichele A, Walch A, Bronger H, Becker I, Waldhör C, Höfler H, Esserman L; I-SPY 1 TRIAL Investigators, Liotta LA, Becker KF, Petricoin EF 3rd.

Clin Cancer Res. 2012 Dec 1;18(23):6426-35. doi: 10.1158/1078-0432.CCR-12-0452. Epub 2012 Oct 8.

28.

Histopathologic features of ovarian borderline tumors are not predictive of clinical outcome.

Avril S, Hahn E, Specht K, Hauptmann S, Höss C, Kiechle M, Höfler H, Schmalfeldt B.

Gynecol Oncol. 2012 Dec;127(3):516-24. doi: 10.1016/j.ygyno.2012.08.027. Epub 2012 Sep 18.

PMID:
23000388
29.

Expression profiling of stem cell-related genes in neoadjuvant-treated gastric cancer: a NOTCH2, GSK3B and β-catenin gene signature predicts survival.

Bauer L, Langer R, Becker K, Hapfelmeier A, Ott K, Novotny A, Höfler H, Keller G.

PLoS One. 2012;7(9):e44566. doi: 10.1371/journal.pone.0044566. Epub 2012 Sep 10.

30.

Proposal for a multifactorial prognostic score that accurately classifies 3 groups of gastric carcinoma patients with different outcomes after neoadjuvant chemotherapy and surgery.

Becker K, Reim D, Novotny A, Zum Büschenfelde CM, Engel J, Friess H, Höfler H, Langer R.

Ann Surg. 2012 Dec;256(6):1002-7. doi: 10.1097/SLA.0b013e318262a591.

PMID:
22968067
31.

Innovations in phenotyping of mouse models in the German Mouse Clinic.

Fuchs H, Gailus-Durner V, Neschen S, Adler T, Afonso LC, Aguilar-Pimentel JA, Becker L, Bohla A, Calzada-Wack J, Cohrs C, Dewert A, Fridrich B, Garrett L, Glasl L, Götz A, Hans W, Hölter SM, Horsch M, Hurt A, Janas E, Janik D, Kahle M, Kistler M, Klein-Rodewald T, Lengger C, Ludwig T, Maier H, Marschall S, Micklich K, Möller G, Naton B, Prehn C, Puk O, Rácz I, Räss M, Rathkolb B, Rozman J, Scheerer M, Schiller E, Schrewe A, Steinkamp R, Stöger C, Sun M, Szymczak W, Treise I, Vargas Panesso IL, Vernaleken AM, Willershäuser M, Wolff-Muscate A, Zeh R, Adamski J, Beckers J, Bekeredjian R, Busch DH, Eickelberg O, Favor J, Graw J, Höfler H, Höschen C, Katus H, Klingenspor M, Klopstock T, Neff F, Ollert M, Schulz H, Stöger T, Wolf E, Wurst W, Yildirim AÖ, Zimmer A, Hrabě de Angelis M.

Mamm Genome. 2012 Oct;23(9-10):611-22. doi: 10.1007/s00335-012-9415-1. Epub 2012 Aug 29.

32.

Evidence of prognostic relevant expression profiles of heat-shock proteins and glucose-regulated proteins in oesophageal adenocarcinomas.

Slotta-Huspenina J, Berg D, Bauer K, Wolff C, Malinowsky K, Bauer L, Drecoll E, Bettstetter M, Feith M, Walch A, Höfler H, Becker KF, Langer R.

PLoS One. 2012;7(7):e41420. doi: 10.1371/journal.pone.0041420. Epub 2012 Jul 24.

33.

Direct molecular tissue analysis by MALDI imaging mass spectrometry in the field of gastrointestinal disease.

Balluff B, Rauser S, Ebert MP, Siveke JT, Höfler H, Walch A.

Gastroenterology. 2012 Sep;143(3):544-549.e2. doi: 10.1053/j.gastro.2012.07.022. Epub 2012 Jul 20. Review. No abstract available.

PMID:
22820311
34.

Common protein biomarkers assessed by reverse phase protein arrays show considerable intratumoral heterogeneity in breast cancer tissues.

Malinowsky K, Raychaudhuri M, Buchner T, Thulke S, Wolff C, Höfler H, Becker KF, Avril S.

PLoS One. 2012;7(7):e40285. doi: 10.1371/journal.pone.0040285. Epub 2012 Jul 5.

35.

Cytochrome c oxidase subunit 4 isoform 2-knockout mice show reduced enzyme activity, airway hyporeactivity, and lung pathology.

Hüttemann M, Lee I, Gao X, Pecina P, Pecinova A, Liu J, Aras S, Sommer N, Sanderson TH, Tost M, Neff F, Aguilar-Pimentel JA, Becker L, Naton B, Rathkolb B, Rozman J, Favor J, Hans W, Prehn C, Puk O, Schrewe A, Sun M, Höfler H, Adamski J, Bekeredjian R, Graw J, Adler T, Busch DH, Klingenspor M, Klopstock T, Ollert M, Wolf E, Fuchs H, Gailus-Durner V, Hrabě de Angelis M, Weissmann N, Doan JW, Bassett DJ, Grossman LI.

FASEB J. 2012 Sep;26(9):3916-30. doi: 10.1096/fj.11-203273. Epub 2012 Jun 22.

36.

Intratumoral heterogeneity of microRNA expression in breast cancer.

Raychaudhuri M, Schuster T, Buchner T, Malinowsky K, Bronger H, Schwarz-Boeger U, Höfler H, Avril S.

J Mol Diagn. 2012 Jul;14(4):376-84. doi: 10.1016/j.jmoldx.2012.01.016. Epub 2012 Jun 15.

PMID:
22704963
37.

Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines.

Kneissl J, Keller S, Lorber T, Heindl S, Keller G, Drexler I, Hapfelmeier A, Höfler H, Luber B.

Int J Oncol. 2012 Aug;41(2):733-44. doi: 10.3892/ijo.2012.1479. Epub 2012 May 14.

PMID:
22614881
38.

High HSP27 and HSP70 expression levels are independent adverse prognostic factors in primary resected colon cancer.

Bauer K, Nitsche U, Slotta-Huspenina J, Drecoll E, von Weyhern CH, Rosenberg R, Höfler H, Langer R.

Cell Oncol (Dordr). 2012 Jun;35(3):197-205. doi: 10.1007/s13402-012-0079-3. Epub 2012 Apr 26.

PMID:
22535481
39.

uPA and PAI-1-Related Signaling Pathways Differ between Primary Breast Cancers and Lymph Node Metastases.

Malinowsky K, Wolff C, Berg D, Schuster T, Walch A, Bronger H, Mannsperger H, Schmidt C, Korf U, Höfler H, Becker KF.

Transl Oncol. 2012 Apr;5(2):98-104. Epub 2012 Apr 1.

40.

Tissue-based proteomics reveals FXYD3, S100A11 and GSTM3 as novel markers for regional lymph node metastasis in colon cancer.

Meding S, Balluff B, Elsner M, Schöne C, Rauser S, Nitsche U, Maak M, Schäfer A, Hauck SM, Ueffing M, Langer R, Höfler H, Friess H, Rosenberg R, Walch A.

J Pathol. 2012 Dec;228(4):459-70. doi: 10.1002/path.4021. Epub 2012 May 23.

PMID:
22430872
41.

Antibody validation by combining immunohistochemistry and protein extraction from formalin-fixed paraffin-embedded tissues.

Schuster C, Malinowsky K, Liebmann S, Berg D, Wolff C, Tran K, Schott C, Reu S, Neumann J, Faber C, Höfler H, Kirchner T, Becker KF, Hlubek F.

Histopathology. 2012 May;60(6B):E37-50. doi: 10.1111/j.1365-2559.2012.04184.x. Epub 2012 Mar 6.

PMID:
22393911
42.

Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay.

Denkert C, Kronenwett R, Schlake W, Bohmann K, Penzel R, Weber KE, Höfler H, Lehmann U, Schirmacher P, Specht K, Rudas M, Kreipe HH, Schraml P, Schlake G, Bago-Horvath Z, Tiecke F, Varga Z, Moch H, Schmidt M, Prinzler J, Kerjaschki D, Sinn BV, Müller BM, Filipits M, Petry C, Dietel M.

Virchows Arch. 2012 Mar;460(3):251-9. doi: 10.1007/s00428-012-1204-4. Epub 2012 Feb 28.

43.

MALDI imaging mass spectrometry reveals COX7A2, TAGLN2 and S100-A10 as novel prognostic markers in Barrett's adenocarcinoma.

Elsner M, Rauser S, Maier S, Schöne C, Balluff B, Meding S, Jung G, Nipp M, Sarioglu H, Maccarrone G, Aichler M, Feuchtinger A, Langer R, Jütting U, Feith M, Küster B, Ueffing M, Zitzelsberger H, Höfler H, Walch A.

J Proteomics. 2012 Aug 3;75(15):4693-704. doi: 10.1016/j.jprot.2012.02.012. Epub 2012 Feb 17.

PMID:
22365974
44.

Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines.

Heindl S, Eggenstein E, Keller S, Kneissl J, Keller G, Mutze K, Rauser S, Gasteiger G, Drexler I, Hapfelmeier A, Höfler H, Luber B.

J Cancer Res Clin Oncol. 2012 May;138(5):843-58. doi: 10.1007/s00432-011-1128-4.

PMID:
22290393
45.

Nucleic acids from long-term preserved FFPE tissues are suitable for downstream analyses.

Ludyga N, Grünwald B, Azimzadeh O, Englert S, Höfler H, Tapio S, Aubele M.

Virchows Arch. 2012 Feb;460(2):131-40. doi: 10.1007/s00428-011-1184-9. Epub 2012 Jan 22.

PMID:
22270699
46.

Tumor classification of six common cancer types based on proteomic profiling by MALDI imaging.

Meding S, Nitsche U, Balluff B, Elsner M, Rauser S, Schöne C, Nipp M, Maak M, Feith M, Ebert MP, Friess H, Langer R, Höfler H, Zitzelsberger H, Rosenberg R, Walch A.

J Proteome Res. 2012 Mar 2;11(3):1996-2003. doi: 10.1021/pr200784p. Epub 2012 Feb 3.

PMID:
22224404
47.

Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Luber B, Deplazes J, Keller G, Walch A, Rauser S, Eichmann M, Langer R, Höfler H, Hegewisch-Becker S, Folprecht G, Wöll E, Decker T, Endlicher E, Lorenzen S, Fend F, Peschel C, Lordick F.

BMC Cancer. 2011 Dec 7;11:509. doi: 10.1186/1471-2407-11-509.

48.

MALDI imaging identifies prognostic seven-protein signature of novel tissue markers in intestinal-type gastric cancer.

Balluff B, Rauser S, Meding S, Elsner M, Schöne C, Feuchtinger A, Schuhmacher C, Novotny A, Jütting U, Maccarrone G, Sarioglu H, Ueffing M, Braselmann H, Zitzelsberger H, Schmid RM, Höfler H, Ebert MP, Walch A.

Am J Pathol. 2011 Dec;179(6):2720-9. doi: 10.1016/j.ajpath.2011.08.032. Epub 2011 Oct 18.

49.

Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues.

Aichler M, Seiler C, Tost M, Siveke J, Mazur PK, Da Silva-Buttkus P, Bartsch DK, Langer P, Chiblak S, Dürr A, Höfler H, Klöppel G, Müller-Decker K, Brielmeier M, Esposito I.

J Pathol. 2012 Apr;226(5):723-34. doi: 10.1002/path.3017. Epub 2012 Jan 17.

PMID:
21984419
50.

S100-A10, thioredoxin, and S100-A6 as biomarkers of papillary thyroid carcinoma with lymph node metastasis identified by MALDI imaging.

Nipp M, Elsner M, Balluff B, Meding S, Sarioglu H, Ueffing M, Rauser S, Unger K, Höfler H, Walch A, Zitzelsberger H.

J Mol Med (Berl). 2012 Feb;90(2):163-74. doi: 10.1007/s00109-011-0815-6. Epub 2011 Sep 22.

PMID:
21938494

Supplemental Content

Loading ...
Support Center